The carcinogen, 2-naphthylamine (2-NA), induces tumor formation in the urinary bladder but not the liver of several species, including humans and dogs. Since its proximate carcinogenic metabolite, N-hydroxy-2-NA, was known to react directly with DNA in vitro to give specific carcinogen-base adducts, we investigated the in vivo formation and persistence of (2-NA)-DNA adducts in the bladder and liver and attempted to determine whether or not these lesions correlated with tissue susceptibility. Male beagle dogs were administered [3H]2-NA and sacrificed after 2 or 7 days. The DNA was isolated from the liver and urothelium and hydrolyzed enzymatically. The (2-NA)-deoxyribonucleoside adducts, which were quantitated by high pressure liquid chromatographic analysis, were the same as those found in vitro, namely 1-(deoxyguanosin-N2-yl)-2-NA, 1-(deoxyadenosin-N6-yl)-2-NA, and an imidazole ring-opened derivative of N-(deoxyguanosin-8-yl)-2-NA. The major difference detected between target and non-target tissues was in the total level of binding to DNA, which was 4-fold higher in the urothelium at 2 days and 8-fold higher at 7 days after 2-NA dosing. Analysis of specific adducts suggested that this difference may be due to the relative persistence of the C-8-guanine adduct in the urothelium as compared to the liver. Similar experiments with the non-carcinogen, 1-naphthylamine, failed to reveal binding in urothelial DNA and indicated a 20-fold lower binding level in hepatic DNA. Evidence for binding of 2-NA to glycogen is also presented and problems associated with measuring total radioactivity in glycogen-contaminated DNA fractions are discussed. The data obtained in this study, through from a necessarily limited number of animals, are consistent with the hypothesis that the formation and persistence of DNA-carcinogen adducts may be important in the initiation of the neoplastic process.

Some seven years have passed since the U.S. legislature mandated the EPA to develop and implement a screening and testing program for chemicals that may disrupt the delicate endocrine system. The envisioned EPA program has evolved to incorporate a tiered scheme of in vitro and in vivo assays, and considered QSAR as a viable method to set testing priorities. At the U.S. FDA's National Center for Toxicological Research (NCTR), the Endocrine Disruptor Knowledge Base Project has developed models to predict estrogen and androgen receptor binding. Our approach rationally integrates various QSAR models into a sequential "Four-Phase" scheme according to the strength of each type of model. In four hierarchical phases, models predict the inactive chemicals that are then eliminated from the pool of chemicals to which increasingly precise but more time-consuming models are subsequently applied. Each phase employs different models selected to work complementarily in representing key activity-determining structure features in order to absolutely minimize the rate of false negatives, an outcome we view as paramount for regulatory use. In this paper, the QSAR models developed at NCTR, and particularly how we integrated these models into the "Four-Phase" system will be discussed for a number of datasets, including 58 000 chemicals identified by the U.S. EPA.

No abstract